Betty C. Pang

In connection with her transactional practice and general representation of healthcare industry clients, Dr. Pang also represents commercial lenders, private equity firms, and investment banks in healthcare transactions.

Over the last several years, Dr. Pang has advised on numerous capital markets, mergers and acquisitions, and finance transactions for the following clients:  

Capital Markets

• Revolution Medicines in its US$230 million public offering
• Imago BioSciences in its US$134.4 million initial public offering
• Aligos Therapeutics in its US$173 million initial public offering
• Prothena in its US$72.6 million offering
• Prometheus Biosciences, Inc. in its US$218 million initial public offering
• Oscar Health, Inc. in its US$1.44 billion initial public offering
• Rhythm Pharmaceuticals, Inc. in its US$172 million common stock offering
• Angion Biomedical in its US$117 million initial public offering
• Sana Biotechnology, Inc. in its US$675 initial public offering
• Revolution Medicines, Inc. in its US$300 million common stock offering
• Arcutis Biotherapeutics, Inc. in its US$183 million common stock offering
• Aimmune Therapeutics in its US$160 million initial public offering
• Ascendis Pharma in its US$500 million initial public offering and subsequent US$500 million convertible notes offering
• Corvus Pharmaceuticals in its US$60 million follow-on offering
• CytomX Therapeutics in its US$116.9 million initial public offering and follow-on offering
• Gritstone Oncology in its US$74.8 million offering
• Teladoc in its US$180 million initial public offering
• Numerous underwriters in various offerings, including:
  • Alpine Immune Sciences' US$100 million public offering
  • Chinook Therapeutics' US$105 million public offering
  • Minerva Surgical’s US$75 million initial public offering
  • Eliem Therapeutics’ initial public offering
  • Petco’s US$279 initial public offering
  • Aclaris Therapeutics, Inc.’s US$25 million at-the-market offering
  • Instil Bio, Inc.’s US$320 million initial public offering
  • Aspira Women’s Health Inc.’s US$52 million common stock offering
  • Vor Biopharma Inc.’s US$203 million initial public offering
  • Halozyme Therapeutics, Inc.’s US$700 million convertible senior notes offering
  • Sientra, Inc.’s US$42 million common stock offering

Mergers and Acquisitions

• Imago BioSciences in its pending US$1.35 billion acquisition by Merck
• CooperCompanies in its acquisition of Cook Medical’s Reproductive Health business
• Eleusis in its US$446 million business combination with Silver Spike Acquisition Corp. II
• Preventice Solutions, Inc. in its US$1.23 billion sale to Boston Scientific
• North American Science Associates, Inc. (NAMSA) in its US$43.5 million acquisition of American Preclinical Services, LLC
• Pionyr Immunotherapeutics in its US$275 million sale to Gilead Sciences
• KKR in its:
  • US$1.4 billion acquisition of PharMerica
  • US$354 million acquisition of Covenant Surgical Partners
• Leonard Green & Partners L.P. in its US$363 million acquisition of Prospect Medical Holdings
• Bonti in its US$195 million sale to Allergan

Finance

• SLR Capital Partners in the US$300 million debt facilities for Outset Medical
• Innocoll Biotherapeutics in its US$125 million term loan provided by funds managed by Oaktree Capital
• JPMorgan in the
  • US$3.65 billion term loan and revolving credit facility for PPD, Inc., a global contract research organization that provides drug discovery, clinical development, lifecycle management, and laboratory services, to refinance existing debt
  • US$38.3 billion term loan facilities in connection with Takeda Pharmaceutical Company Limited's acquisition of Shire plc, an Ireland-based biopharmaceutical company
• Deutsche Bank in the incremental term loan and revolving credit facility in connection with Endo Limited's acquisition of Par Pharmaceutical Holdings, Inc., a specialty pharmaceutical company
• Bank of America and Merrill Lynch, Fenner, Pierce & Smith in the US$3 billion term loan and revolving credit facilities in connection with Gilead Science’s US$11.2 billion acquisition of Pharmasset, Inc., a clinical stage pharmaceutical company focused primarily on developing oral therapeutics for the treatment of hepatitis C